Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe ...

For many investors, the main point of stock picking is to generate higher returns than the overall market. But in ...

Parnassus Investments, an investment management firm that focuses on owning a concentrated portfolio of U.S. large cap stocks ...

One relatively safe bet about how Pfizer's lineup will look different five years from now is that the company will be a ...

Pfizer faces weak growth, sector headwinds, and pipeline uncertainty despite cost cuts and a 7% yield, weighing on sentiment.

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

Shares of Pfizer Inc. PFE slid 2.18% to $23.29 Thursday, on what proved to be an all-around dismal trading session for the ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Do you know how hard it is to find a stock as bad as Pfizer Inc (NYSE:PFE) like in the last couple of years? I managed the ...

Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

Pfizer Inc. (NYSE:PFE) hasn’t performed well in recent years, with its stock declining more than 26% over the past decade.

Pfizer has an analyst consensus of Hold, with a price target consensus of $28.50, implying a 14.97% upside from current levels. In a report released yesterday, Bernstein also maintained a Hold rating ...